Korean J Pediatr.  2015 Aug;58(8):275-282. 10.3345/kjp.2015.58.8.275.

Nephrotic syndrome: what's new, what's hot?

Affiliations
  • 1Department of Pediatrics, Research Coordination Center for Rare Diseases, Seoul National University Children's Hospital, Seoul, Korea. cheonghi@snu.ac.kr

Abstract

While the incidence of nephrotic syndrome (NS) is decreasing in Korea, the morbidity of difficult-to-treat NS is significant. Efforts to minimize treatment toxicity showed that prolonged treatment after an initial treatment for 2-3 months with glucocorticosteroids was not effective in reducing frequent relapses. For steroid-dependent NS, rituximab, a monoclonal antibody against the CD20 antigen on B cells, was proven to be as effective, and short-term daily low-dose steroids during upper respiratory infections reduced relapses. Steroid resistance or congenital NS are indications for genetic study and renal biopsy, since the list of genes involved in NS is lengthening.

Keyword

Nephrotic syndrome; Rituximab; Prednisolone

MeSH Terms

Antigens, CD20
B-Lymphocytes
Biopsy
Incidence
Korea
Nephrotic Syndrome*
Prednisolone
Recurrence
Respiratory Tract Infections
Steroids
Rituximab
Antigens, CD20
Prednisolone
Steroids
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr